GNX 5086
Alternative Names: GNX-5086Latest Information Update: 04 Nov 2017
At a glance
- Originator Congenia
- Class Anti-ischaemics; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Mitochondrial permeability transition pore inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myocardial reperfusion injury
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Myocardial reperfusion injury(In volunteers) in Netherlands (IV)
- 15 Aug 2013 Phase-I clinical trials in Myocardial reperfusion injury (in volunteers) in Netherlands (IV)
- 24 Jul 2013 Regulatory authorities in the Netherlands approve CTA for GNX-5086 in Myocardial reperfusion injury